Informações:
Falhas:
ID
35467
Descrição
Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients; ODM derived from: https://clinicaltrials.gov/show/NCT02376452
Link
https://clinicaltrials.gov/show/NCT02376452
Palavras-chave
Versões (1)
- 05/03/2019 05/03/2019 -
Titular dos direitos
See clinicaltrials.gov
Transferido a
5 de março de 2019
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Colorectal Carcinoma NCT02376452
Eligibility Colorectal Carcinoma NCT02376452
- StudyEvent: Eligibility
Similar models
Eligibility Colorectal Carcinoma NCT02376452
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Age | Adenocarcinoma of large intestine Advanced
Item
aged 18-70 years with histologically or cytologically confirmed advanced colorectal adenocarcinoma
boolean
C0001779 (UMLS CUI [1])
C1319315 (UMLS CUI [2,1])
C0205179 (UMLS CUI [2,2])
C1319315 (UMLS CUI [2,1])
C0205179 (UMLS CUI [2,2])
ECOG performance status
Item
eastern cooperative oncology group performance status of 0 to 1
boolean
C1520224 (UMLS CUI [1])
Life Expectancy
Item
life expectancy of ≥ 3 months
boolean
C0023671 (UMLS CUI [1])
First line treatment failed | Xeloda-Oxaliplatin Regimen | FOLFOX Regimen
Item
patients who had failed first-line treatment with either xelox (capecitabine combined with oxaliplatin) or folfox (5-fluorouracil/leucovorin with oxaliplatin)
boolean
C1708063 (UMLS CUI [1,1])
C0231175 (UMLS CUI [1,2])
C1956962 (UMLS CUI [2])
C0392943 (UMLS CUI [3])
C0231175 (UMLS CUI [1,2])
C1956962 (UMLS CUI [2])
C0392943 (UMLS CUI [3])
Measurable lesion Quantity
Item
at least one measurable disease lesion according to the response evaluation criteria in solid tumors (recist 1.1) criteria
boolean
C1513041 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,2])
Bone Marrow function | Liver function | Renal function
Item
have adequate bone marrow, hepatic, and renal function
boolean
C0005953 (UMLS CUI [1,1])
C0031843 (UMLS CUI [1,2])
C0232741 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
C0031843 (UMLS CUI [1,2])
C0232741 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
Chronic inflammatory bowel disease | Chronic diarrhea | Intestinal Obstruction Recurrent
Item
patients with previous chronic inflammatory bowel disease, chronic diarrhea or recurrent bowel obstruction
boolean
C1856359 (UMLS CUI [1])
C0401151 (UMLS CUI [2])
C0021843 (UMLS CUI [3,1])
C2945760 (UMLS CUI [3,2])
C0401151 (UMLS CUI [2])
C0021843 (UMLS CUI [3,1])
C2945760 (UMLS CUI [3,2])
Metastatic malignant neoplasm to brain Symptomatic
Item
patients with symptomatic brain metastases
boolean
C0220650 (UMLS CUI [1,1])
C0231220 (UMLS CUI [1,2])
C0231220 (UMLS CUI [1,2])
Communicable Disease Severe
Item
active clinical severe infection
boolean
C0009450 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0205082 (UMLS CUI [1,2])
irinotecan | raltitrexed
Item
previously received irinotecan or raltitrexed
boolean
C0123931 (UMLS CUI [1])
C0677667 (UMLS CUI [2])
C0677667 (UMLS CUI [2])
Dihydropyrimidine dehydrogenase Adequate
Item
dihydropyrimidine dehydrogenase (dpd) enzyme adequate
boolean
C0058126 (UMLS CUI [1,1])
C0205411 (UMLS CUI [1,2])
C0205411 (UMLS CUI [1,2])